MPNs

Updated 96-week data from the ASC4FIRST trial show asciminib significantly outperforms standard TKIs in major molecular response for patients with CML.

Cladribine plus venetoclax improved complete response and CR with incomplete count recovery rates in MRD-negative patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Selinexor with ruxolitinib demonstrated encouraging efficacy with a manageable safety profile in patients with myelofibrosis who were previously treated with ruxolitinib.

Venetoclax with hypomethylating agents produced better responses than HMAs alone in adult patients with myelodysplastic syndrome.

In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.

Olverembatinib demonstrates potential as a safe, effective second-line therapy for chronic-phase CML after resistance to second-generation TKIs, according to ChiCTR2200061655 trial data.

The phase 2 LODEFI study showed that low-dose deferasirox achieved transfusion independence and was well-tolerated in low-risk anemic MDS.

TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily pre-treated patients with chronic myeloid leukemia.

R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS in patients with inadequate responses to prior therapies.

The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly diagnosed Ph-positive CP- and AP-CML, or for those resistant or intolerant to prior therapy, including imatinib.

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for high-risk myelodysplastic syndrome, leading to the trial being discontinued.

In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid leukemia treatment.

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed following treatment with a type I JAK2 inhibitor.

A phase 1 study of tapotoclax in high-risk myelodysplastic syndromes demonstrated the agent was tolerable but showed limited efficacy.

Asciminib has gained accelerated approval from the FDA for the treatment of patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

The FREEDOM2 study demonstrates that fedratinib is an effective second-line treatment for myelofibrosis after ruxolitinib failure or intolerance.

In an interview, Prithviraj Bose, MD, discussed the multiple JAK inhibitors available for the treatment of patients with myeloproliferative neoplasms.

Despite recent setbacks in clinical trials, there is still hope for improving treatments for high-risk myelodysplastic syndromes.

Experts review the case of a 68-year-old woman diagnosed with primary myelofibrosis.

The phase 3 Shorespan-007 trial will compare bomedemstat with hydroxyurea in patients with treatment-naive essential thrombocythemia.

Tebapivat, a novel pyruvate kinase activator, is being investigated for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

Imetelstat sustained red blood cell transfusion independence in patients with lower-risk myelodysplastic syndrome, with most responders experiencing durable responses.

During a Case-Based Roundtable® event, Gabriela S. Hobbs, MD, surveyed physicians on the disease features that are most challenging in primary myelofibrosis in the first article of a 2-part series.

During a Case-Based Roundtable® event, Jeanne M. Palmer, MD, moderated a discussion on challenging symptoms of myelofibrosis and when to initiate treatment with JAK inhibitors.

In an interview with Targeted Oncology, John Mascarenhas, MD, discussed the lead up to the SENTRY trial and its potential impact on the treatment of myelofibrosis.

During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.

In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.

During a Case-Based Roundtable® event, Kristen Pettit, MD, discussed the use of pacritinib and momelotinib in cytopenic myelofibrosis in the second article of a 2-part series.

Disease duration, thrombotic event history, elevated WBC count, HCT levels, and VAF are key predictors of polycythemia vera progression.

New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.